Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Fig. 2

Incidence of neutropenia (neutropenia includes the following preferred terms: neutropenia and neutrophil count decreased) before and after palbociclib dose reduction from 125 to 100 mg. C, cycle occurring after the dose reduction

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us